IBA (Ion Beam Applications) a provider of proton therapy solutions for the treatment of cancer, has signed a contract with Quirónsalud, Spain’s leading hospital group and part of Germany’s Helios Group, to install a ProteusONE* compact proton therapy solution in Madrid.
The contract covers delivery of a Proteus ONE solution, including latest generation pencil-beam scanning (PBS), isocenter volumetric imaging (cone-beam CT) capabilities and a long-term maintenance agreement. The hospital group will also benefit from Penn Medicine and IBA’s proton therapy clinical education program. The hospital will be ready to start treating patients by 2019.
The typical end-user price for a ProteusONE system with a maintenance contract is between EUR 35 and 40 million. This will be IBA’s 18th installation of the compact single-room proton therapy solution.
Olivier Legrain, CEO of IBA, commented: “IBA’s first entry into the Spanish market demonstrates the ongoing appeal of IBA’s single-room solution, ProteusONE."
Leticia Moral Iglesias, general director of Care, Quality and Innovation of Quirónsalud group, commented: “This innovative technology will enable us to ‘paint’ tumours with a super-fine beam of protons, destroying the cancer cells whilst limiting the exposure of healthy tissues surrounding the tumor and reducing the risk of secondary cancers. At Quirónsalud, we believe that this state-of-the-art technology will also attract patients from other countries.”Back To Top
IBA to install Spain’s first proton therapy center. Appl Rad Oncol.